Cancers Ramp Up Overall mRNA Expression as They Progress

A technique for quantifying tumor mRNA production from messy tissue sample data uncovers an unexpected correlation between it and disease stage in 15 cancer types.

Written byDan Robitzski
| 4 min read
3D rendering of a scanning electron micrograph of pink malignant cancer cells against a black background
Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The amount of mRNA expressed by a tumor seems to serve as a reliable indicator of disease progression, a new analysis of human tissue sample finds. The correlation, which researchers identified for 15 types of cancer, was enabled by a new statistical technique that helps make sense of massive sets of convoluted data.

Unlike research conducted on the homogenous tumors that cancer scientists can grow in a lab and use as experimental models, studying cancers that grow in humans can be a messy affair. Cancer cells, microbiota, and human immune cells can all exist in close proximity to one another, and researchers attempting to sequence the tumor cells typically choose between bulk sequencing, which yields difficult-to-interpret data, or single-cell sequencing, which quickly becomes costly in terms of both time and money. The new technique, however, can pull useful information out of bulk data generated from human cancer samples and provide ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • black and white image of young man in sunglasses with trees in background

    Dan is an award-winning journalist based in Los Angeles who joined The Scientist as a reporter and editor in 2021. Ironically, Dan’s undergraduate degree and brief career in neuroscience inspired him to write about research rather than conduct it, culminating in him earning a master’s degree in science journalism from New York University in 2017. In 2018, an Undark feature Dan and colleagues began at NYU on a questionable drug approval decision at the FDA won first place in the student category of the Association of Health Care Journalists' Awards for Excellence in Health Care Journalism. Now, Dan writes and edits stories on all aspects of the life sciences for the online news desk, and he oversees the “The Literature” and “Modus Operandi” sections of the monthly TS Digest and quarterly print magazine. Read more of his work at danrobitzski.com.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies